Nymox Pharmaceutical Corp

NYMXF OTC SEC CIK 1018735
Follow Nymox Pharmaceutical Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2024 USD · IFRS
Net income −$857K +83.9% vs same quarter last year
EPS, diluted -
Operating cash flow −$717K +20.1% vs same quarter last year
Net income by quarter
−$5.3M
−$857K
Q4 23 Q4 24

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10MFY14FY16FY18FY20FY22FY24
Show the numbers
YearRevenueNet income
FY24-−$4.5M
FY23$0−$8.8M
FY22$0−$6.6M
FY21$0−$12.5M
FY20$5K−$11.7M
FY19$116K−$13.2M
FY18$299K−$10.6M
FY17$224K−$13.4M
FY16$284K−$13.1M
FY15$2.8M−$17.9M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300000%−200000%−100000%0%100000%FY14FY16FY18FY20FY22FY24
Show the numbers
YearGross marginOperating marginNet margin
FY24---
FY23---
FY22---
FY21---
FY2020%−234400%−234760%
FY1950%−11487.1%−11346.6%
FY1853.8%−3558.9%−3543.1%
FY1733.5%−5908.5%−5995.1%
FY1639.1%−4531.3%−4616.2%
FY1594.2%−639.6%−648.1%
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY14FY16FY18FY20FY22FY24
Show the numbers
YearFree cash flow
FY24−$2.6M
FY23−$4.1M
FY22−$5.2M
FY21−$9.8M
FY20−$10.1M
FY19−$7.4M
FY18−$7.8M
FY17-
FY16−$4.5M
FY15-
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Nymox Pharmaceutical
  • Healthcare median
−300000%−200000%−100000%0%FY14FY16FY18FY20FY22FY24
Show the numbers
YearNymox PharmaceuticalHealthcare median
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20−234760%−62.2%
FY19−11346.6%−46.3%
FY18−3543.1%−49.6%
FY17−5995.1%−45.9%
FY16−4616.2%−36%
FY15−648.1%−38.4%
FY14-−35.5%